275 related articles for article (PubMed ID: 32864098)
21. Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions.
Dahmen H; Horsten U; Küster A; Jacques Y; Minvielle S; Kerr IM; Ciliberto G; Paonessa G; Heinrich PC; Müller-Newen G
Biochem J; 1998 May; 331 ( Pt 3)(Pt 3):695-702. PubMed ID: 9560294
[TBL] [Abstract][Full Text] [Related]
22. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure.
Lei CT; Su H; Ye C; Tang H; Gao P; Wan C; He FF; Wang YM; Zhang C
J Cell Mol Med; 2018 Jan; 22(1):251-260. PubMed ID: 28881473
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-6, its role in fibrosing conditions.
O'Reilly S; Ciechomska M; Cant R; Hügle T; van Laar JM
Cytokine Growth Factor Rev; 2012 Jun; 23(3):99-107. PubMed ID: 22561547
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-6--a key regulator of colorectal cancer development.
Waldner MJ; Foersch S; Neurath MF
Int J Biol Sci; 2012; 8(9):1248-53. PubMed ID: 23136553
[TBL] [Abstract][Full Text] [Related]
25. Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase.
Giordano V; De Falco G; Chiari R; Quinto I; Pelicci PG; Bartholomew L; Delmastro P; Gadina M; Scala G
J Immunol; 1997 May; 158(9):4097-103. PubMed ID: 9126968
[TBL] [Abstract][Full Text] [Related]
26. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
[TBL] [Abstract][Full Text] [Related]
27. EGFR stimulation enables IL-6 trans-signalling via iRhom2-dependent ADAM17 activation in mammary epithelial cells.
Schumacher N; Thomsen I; Brundert F; Hejret V; Düsterhöft S; Tichý B; Schmidt-Arras D; Voss M; Rose-John S
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119489. PubMed ID: 37271223
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 and its receptor: from bench to bedside.
Scheller J; Rose-John S
Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
[TBL] [Abstract][Full Text] [Related]
29. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.
Kallen KJ
Biochim Biophys Acta; 2002 Nov; 1592(3):323-43. PubMed ID: 12421676
[TBL] [Abstract][Full Text] [Related]
30. Proteolytic control of Interleukin-11 and Interleukin-6 biology.
Lokau J; Agthe M; Flynn CM; Garbers C
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2105-2117. PubMed ID: 28630024
[TBL] [Abstract][Full Text] [Related]
31. Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation.
Pflanz S; Kurth I; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 2000 Dec; 165(12):7042-9. PubMed ID: 11120832
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
33. [Immune Regulation by TNF Receptor-associated Factor 5].
So T
Yakugaku Zasshi; 2024; 144(5):489-496. PubMed ID: 38692922
[TBL] [Abstract][Full Text] [Related]
34. The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling.
Fischer P; Lehmann U; Sobota RM; Schmitz J; Niemand C; Linnemann S; Haan S; Behrmann I; Yoshimura A; Johnston JA; Müller-Newen G; Heinrich PC; Schaper F
Biochem J; 2004 Mar; 378(Pt 2):449-60. PubMed ID: 14611646
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.
Heinrich PC; Behrmann I; Müller-Newen G; Schaper F; Graeve L
Biochem J; 1998 Sep; 334 ( Pt 2)(Pt 2):297-314. PubMed ID: 9716487
[TBL] [Abstract][Full Text] [Related]
36. Physiological effects of modulating the interleukin-6 axis.
Schett G
Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii43-ii50. PubMed ID: 29982781
[TBL] [Abstract][Full Text] [Related]
37. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling.
Li H; Wang H; Nicholas J
J Virol; 2001 Apr; 75(7):3325-34. PubMed ID: 11238858
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterization of grass carp interleukin-6 receptor and the agonistic activity of its soluble form in head kidney leucocytes.
Wang X; Guo Y; Wen C; Lv M; Gan N; Zhou H; Zhang A; Yang K
Fish Shellfish Immunol; 2019 Mar; 86():1072-1080. PubMed ID: 30576778
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line.
Nakanishi H; Yoshioka K; Joyama S; Araki N; Myoui A; Ishiguro S; Ueda T; Yoshikawa H; Itoh K
Am J Pathol; 2004 Aug; 165(2):471-80. PubMed ID: 15277221
[TBL] [Abstract][Full Text] [Related]
40. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
Int Immunol; 1996 Apr; 8(4):595-602. PubMed ID: 8722639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
